Poison control calls related to GLP-1 receptor agonists (GLP-1RAs) surged from roughly 1,000-1,500 cases annually before 2021 to over 8,000 cases by 2023, according to research led by Jordan Miller and David Han of UT San Antonio. The spike correlates with the 2021 FDA approval of semaglutide for chronic weight management, which expanded the drug’s use beyond type 2 diabetes patients.
Why did semaglutide cause a spike in poison control calls?
The increase in calls stems largely from patient misuse and mishandling following the expanded FDA approval. David Han, Romo Endowed Professor in the UT San Antonio Department of Statistics & Data Science, stated that the call volume skyrocketed because the drug’s use shifted toward a much larger population seeking weight loss.
Research conducted by Jordan Miller, in collaboration with the South Texas Poison Center, found that semaglutide was “incredibly dominant” compared to other medications in this category. The team attributes this trend to the massive media attention surrounding the drug’s weight-loss capabilities.
What are the most common dosing mistakes?
Many poison control incidents were preventable errors caused by a lack of patient education. According to the study, which appeared in the Journal of Medical Toxicology, two specific mistakes were most prevalent:
- Frequency Errors: Patients injected the medication daily instead of the prescribed once-weekly dose.
- Dosing Escalation: Patients started immediately with the highest dose rather than following the required step-by-step gradual increase.
“Can you imagine something you’re supposed to trickle up to, and you’re going full blast and seven times more often than you’re supposed to?” Jordan Miller noted regarding the severity of these dosing errors.
How does this impact public health moving forward?
The research suggests that the risk can be contained through better education at the point of prescription. Professor David Han emphasized that the public needs more information because the long-term safety and biological behavior of these drugs aren’t fully understood yet.
The study underscores a critical gap in the prescribing process. The researchers argue that improving communication from the doctor’s office to the pharmacy counter is essential to prevent medication errors as these drugs become more common.
Comparing GLP-1RA Trends: Diabetes vs. Weight Loss
The data reveals a sharp contrast in how the drug is handled based on the patient’s diagnosis. According to David Han, there is a “completely different story” when drugs are sold to diabetic patients versus those using them for weight management.
| Period | Annual Poison Control Calls |
|---|---|
| Pre-2021 | 1,000 – 1,500 |
| By 2023 | 8,000+ |
Frequently Asked Questions
Is semaglutide dangerous?
When used as directed, it is FDA-approved. However, the UT San Antonio study found that misuse—such as daily dosing instead of weekly—leads to a significant increase in poison control calls.
Why are poison control calls increasing?
According to the research, the surge is linked to the expanded use of the drug for weight management and a lack of adequate patient education on dosing schedules.
Where was this research published?
The findings were published in the Journal of Medical Toxicology and featured as the cover story in Significance, the magazine of the Royal Statistical Society and the American Statistical Association.
Want to stay informed on the latest medical data and public health trends? Subscribe to our newsletter or leave a comment below with your thoughts on the rise of GLP-1 medications.
